Who and when should we screen for prostate cancer? Interviews with key opinion leaders.

Carlsson S, Leapman M, Carroll P, Schröder F, Albertsen PC, Ilic D, Barry M, Frosch DL, Vickers A., BMC Med. 13:288. doi: 10.1186/s12916-015-0526-x., 2015 Nov 27

Abstract

Prostate cancer screening using prostate-specific antigen (PSA) is highly controversial.

In this Q & A, Guest Editors for BMC Medicine's 'Spotlight on Prostate Cancer' article collection, Sigrid Carlsson and Andrew Vickers, invite some of the world's key opinion leaders to discuss who, and when, to screen for prostate cancer.
In response to the points of view from the invited experts, the Guest Editors summarize the experts' views and give their own personal opinions on PSA screening.

Pubmed Abstract

Pubmed AbstractOpens New Window

Associated Topics

Related Publications

Breast cancer chemoprevention in primary care - assessing readiness for change.

Wang H, Snyder CF, Larson S, Vogel V, Kirchner HL, Sun H, Yan X. 24(6):283-288.
Qual Prim Care.
2016 Nov 01

Adiposity, inflammation, genetic variants and risk of post-menopausal breast cancer findings from a prospective-specimen-collection, retrospective-blinded-evaluation (PRoBE) design approach.

Yan XS, Barnholtz-Sloan J, Chu X, Li L, Colonie R, Webster J, Smelser D, Patel N, Prichard J, Stark A.
Springerplus. 2:638. doi: 10.1186/2193-1801-2-638. eCollection 2013.
2013 Nov 27